Skip to main content

Optain Health

Category: AI in Healthcare

AI-powered healthcare technology leveraging retinal imaging for early detection and prevention of diseases. Optain Health was founded in 2023. The company is led by Jeff Dunkel. Based in New York, USA & Melbourne, Australia. Team size: 51-200. Total funding raised: $26 million. Latest round: Series A, $26.0M, 2025-09, led by Insight Partners. Key investors include ["Insight Partners","Aegis Ventures","Northwell Holdings"].

Founded
2023
Headquarters
New York, USA & Melbourne, Australia
Team size
51-200
Total funding
$26 million

Value proposition

Enable early, non-invasive detection of eye and systemic diseases through AI-driven retinal imaging, improving patient outcomes and reducing healthcare costs.

Products and solutions

["Resolve: A portable, FDA-cleared robotic retinal camera for use in primary care with no patient dilation required.","Assure: AI diagnostic software analyzing retinal images for diseases like diabetic retinopathy, glaucoma, AMD, and cardiovascular conditions.","Teleophthalmology Platform: Connects primary care providers with ophthalmologists for rapid remote image review."]

Unique value

An integrated end-to-end platform combining a user-friendly robotic retinal camera with advanced AI diagnostics and teleophthalmology to enable systemic health insights from eye imaging in primary care.

Target customer

Primary care providers, specialty clinics including endocrinology and cardiology, and health systems.

Industries served

["Healthcare Technology","Medical Devices","Artificial Intelligence"]

Technology advantage

Proprietary AI algorithms detecting a wide range of eye and systemic diseases from a single retinal image, with strategic partnerships enabling rapid clinical adoption and accessible diagnostics.

How they differentiate

Combines FDA-cleared robotic retinal imaging with advanced AI software to enable non-invasive early detection of eye and systemic diseases within primary care settings.

Main competitors

["Forus Health","Remidio","Ibis Vision"]

Key partnerships

["Aegis Ventures (Co-founder and investor)","Northwell Holdings (Co-founder and investor)","Insight Partners (Lead investor for Series A)","Consortium of seven major U.S. health systems (Strategic partners and investors)"]

Notable customers

["Seven major U.S. health systems, including Northwell Health."]

Major milestones

["Raised $26 million in an oversubscribed Series A funding round.","Received FDA clearance for Resolve robotic retinal camera.","Launched AI-powered diagnostic software platform."]

Growth metrics

Specific growth metrics are not publicly disclosed.

Market positioning

Positioned as a preventative health technology company focusing on 'oculomics,' embedding specialist-level diagnostics into routine primary care visits for earlier intervention.

Geographic focus

Primarily United States, with headquarters in New York and partnerships involving major U.S. health systems.

Patents and IP

No specific patent numbers publicly available; technology is supported by over a decade of research and 30+ peer-reviewed publications indicating strong proprietary IP.

About Jeff Dunkel

Jeff Dunkel serves as the Global CEO of Optain Health. His prior experience includes the role of CEO at NuHope, focusing on innovative outpatient approaches. He is also a member of the Global Health Crisis Coordination Center (GHC3).

Official website: